Notably, in DLBCL, for which two different treatment regimens (R-CHOP and DA-EPOCH-R) were used, the observed differences between the two treatment groups point towards a stronger and/or more rapid effect of R-CHOP on glucose metabolism and diffusivity/cell density of the lymphomas in this early phase, which seems plausible because, with R-CHOP, both rituximab and the chemotherapeutic agents were administered on day 1, whereas with DA-EPOCH-R, rituximab was administered on day 1, and the chemotherapeutic agents were administered over 5 days. The gene discussed is DDIT3; the disease is lymphoma.